Maravai secures CleanCap patent and reports on Maravai LifeSciences stock

Published on 10/01/2026 at 12:13 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Maravai LifeSciences stock was EUR 6.73 on October 1, 2026. Q2 revenue was USD 51.44 million, with guidance at USD 33 million-USD 35 million.

MRVI, US56600D1072, Illustration mit AI erstellt.

Maravai secures a China patent for CleanCap and reports on Maravai LifeSciences stock. The additional composition-of-matter protection was announced on September 29, 2026, while the company continues to build its financial case around higher-margin nucleic-acid products.

CleanCap patent adds a concrete asset

According to Maravai LifeSciences on September 29, 2026, TriLink BioTechnologies secured an additional China patent for CleanCap technology. The company said the patent adds broad composition-of-matter protection, strengthening its intellectual-property position in a market it identifies as strategically important.

The patent matters because CleanCap is part of Maravai's nucleic-acid production portfolio, which supports messenger RNA research, clinical development and manufacturing. The investor-relations page also identifies TriLink, Glen Research, Cygnus Technologies and Alphazyme as core brands serving biopharmaceutical and diagnostics customers.

Q2 shows the operating reset

Maravai generated USD 51.44 million of revenue in the second quarter of 2026, compared with USD 48.67 million expected by analysts, according to MarketBeat on September 18, 2026. The adjusted loss was USD 0.02 per share versus a USD 0.04 consensus loss, giving revenue a USD 2.77 million comparison advantage.

The Q2 earnings call added a more forward-looking signal. According to Yahoo Finance on August 6, 2026, adjusted EBITDA reached USD 8.70 million, improving by more than USD 19.00 million year over year. Management raised full-year adjusted EBITDA guidance to USD 33 million-USD 35 million while maintaining 2026 revenue guidance of USD 205 million-USD 215 million.

Stock stays below the yearly high

Maravai LifeSciences stock was trading at EUR 6.73 at Lang & Schwarz on October 1, 2026 at 12:06 p.m. CEST. The quote had no valid prior-close comparison in the same euro data set, so the reference remains the intraday price rather than a daily percentage move.